GABARAPL1 and Alzheimer disease: The GSEA findings (Fig 9, S2 Fig, S7 Table) indicate that GABARAPL1 is significantly enriched in immune-related pathways in AD, encompassing pathways such as autoimmune thyroid disease and cytokine-cytokine receptor interaction.